- Pharmacotherapy used in obesity management.
| Drugs | Starting doses | Available doses | Side effects | Contraindications |
|---|---|---|---|---|
| Orlistat | 120mg TDS | 120 mg | Steatorrhea, oil spots, faecal incontinence, fat-soluble vitamin malabsorption, and flatulence with discharge | Pregnancy |
| Liraglutide | 0.6 mg | 0.6-3mg | Nausea, vomiting, diarrhoea, constipation, pancreatitis (rare), and cholecystitis (rare) | Severe renal or hepatic insufficiency, pregnancy, history of pancreatitis, and psychiatric disorder |
| Lorcaserin | 10 mg BID | 10 mg | Dry mouth, dizziness, somnolence, headache, and gastrointestinal disturbances | Severe renal insufficiency or severe hepatic impairment, pregnant |
| Phenteramine/topiramate | 15 mg/12.5 mg | Phe-15 mg Topi-12.5, 25, 50, 100 mg | Dry mouth, insomnia, agitation, constipation, and tachycardia | Severe hypertension, cardiovascular disease, glaucoma, history of drug or alcohol abuse, monoamine oxidase inhibitors, selective serotonin reuptake inhibitor use, and pregnancy |
| Natrexone/bupropion | 8 mg/90 mg | Nal-8 mg Bup-90 mg | Constipation, diarrhoea, nausea, vomiting, dizziness, and anxiety | Acute opiate withdrawal, allergy to bupropion, bulimia, anorexia nervosa, history of seizure disorder, and uncontrolled hypertension |
| Semaglutide | 0.25 mg SQ once weekly then titrate | 2.4 mg | Hypoglycaemia, abdominal pain, constipation, and nausea | Personal or family history of medullary thyroid carcinoma, known hypersensitivity to semaglutide |
TDS: once 3 times a day, BID: twice a day, Phe: phenteramine, Topi: topiramate, Nal: naltrexone, Bup: bupropion, SQ: subcutaneous